Bioequivalence study of vonoprazan fumarate tablets in healthy Chinese subjects: a randomized, open-label, two-period crossover trial
Frontiers in Pharmacology · 10.07.2026 · 17
DOI: 10.3389/fphar.2026.1855889 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.07.2026. Verfasst von Jin Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzh…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Objectives
To evaluate the bioequivalence and safety of a test formulation (Vonoprazan Fumarate Tablets, 20 mg, T) compared with the reference product (Takecab®, 20 mg, R) in healthy Chinese subjects under both fasting and fed conditions.
Methods
This was a single-center, randomized, open-label, single-dose, two-sequence, two-period, crossover study. Seventy-two healthy subjects were enrolled and assigned to either a fasting (n = 32) or a fed (n = 40) cohort. In each period, subjects received a single dose of either the test (T) or reference (R) formulation, separated by a 5-day washout period before crossing over to the alternate treatment. Plasma vonoprazan concentrations were quantified using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. Pharmacokinetic parameters were calculated using non-compartmental analysis. Bioequivalence was assessed by determining whether the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs, T/R) of C max , AUC 0-t , and AUC 0 ‐ ∞ fell within the predefined range of 80%–125%.
Results
Seventy of the 72 enrolled subjects completed the study. Under fasting conditions, the GMRs (90% CIs) for C max , AUC 0-t , and AUC 0 ‐ ∞ were 95.45% (88.96%–102.41%), 98.15% (93.93%–102.56%), and 98.53% (94.41%–102.83%), respectively. Under fed conditions, the corresponding values were 105.00% (94.35%–116.85%) for C max , 101.96% (98.10%–105.97%) for AUC 0-t , and 102.31% (98.58%–106.17%) for AUC 0 ‐ ∞ . All 90% CIs fell within the accepted bioequivalence limits. Adverse events (AEs) were infrequent, with incidence rates of 28.1% and 25.6% in the fasting and fed groups, respectively; no serious adverse events occurred.
Conclusion
The test formulation of vonoprazan fumarate is bioequivalent to the reference formulation and is well tolerated in healthy Chinese subjects under fasting and fed conditions. Clinical trial registration https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml , identifier CTR20233597.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Clinical Pharmacy, Cancer Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Center for Clinical Pharmacy, Cancer Center, I Phase Clinical Trials Ward, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Haikou Pharmaceutical Factory Co., Ltd., Haikou, Hainan, China.
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Yu, J., Lin, S., Luo, Y., Deng, Y., Yin, H., Sun, H., Yu, J., & Zhang, Y. (2026). Bioequivalence study of vonoprazan fumarate tablets in healthy Chinese subjects: a randomized, open-label, two-period crossover trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1855889
Vancouver
Yu J, Lin S, Luo Y, Deng Y, Yin H, Sun H, et al. Bioequivalence study of vonoprazan fumarate tablets in healthy Chinese subjects: a randomized, open-label, two-period crossover trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1855889
BibTeX
@article{Yu2026,
author = {Yu, Jin and Lin, Sisi and Luo, Yongjie and Deng, Yamin and Yin, Haifeng and Sun, Hong and Yu, Jingzhi and Zhang, Yiwen},
title = {Bioequivalence study of vonoprazan fumarate tablets in healthy Chinese subjects: a randomized, open-label, two-period crossover trial},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1855889}
}
EUVIMED